

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/355170904>

LC/MS–MS Analyses and in vitro anticancer activity of Tourneuxia variifolia extracts View supplementary material LC/MS–MS Analyses and in vitro anticancer activity of Tourneuxia va...

Article in Natural Product Research · October 2021

DOI: 10.1080/14786419.2021.1986818

CITATIONS

0

READS

3

12 authors, including:



Sara Zerrouki

University of Constantine 1

1 PUBLICATION 0 CITATIONS

SEE PROFILE



Mustafa Abdullah Yilmaz

Dicle University

73 PUBLICATIONS 737 CITATIONS

SEE PROFILE


Some of the authors of this publication are also working on these related projects:



Anticancer agents production on Pistacia lentiscus L. [View project](#)



Güneydoğu Anadolu Bölgesi Çekirdekli Kurutmalık Üzümünün Antioksidan Kapasitesi ile Vitamin ve Mineral İçeriğinin Analizi [View project](#)



Natural Product Research

Formerly Natural Product Letters

ISSN: (Print) (Online) Journal homepage: <https://www.tandfonline.com/loi/gnpl20>

LC/MS-MS Analyses and *in vitro* anticancer activity of *Tourneuxia variifolia* extracts

Sara Zerrouki, Samia Mezhoud, Mustafa Abdullah Yilmaz, Ayse Sahin Yaglioglu, Derya Bakir, Ibrahim Demirtas & Ratiba Mekkiou

To cite this article: Sara Zerrouki, Samia Mezhoud, Mustafa Abdullah Yilmaz, Ayse Sahin Yaglioglu, Derya Bakir, Ibrahim Demirtas & Ratiba Mekkiou (2021): LC/MS-MS Analyses and *in vitro* anticancer activity of *Tourneuxia variifolia* extracts, Natural Product Research, DOI: [10.1080/14786419.2021.1986818](https://doi.org/10.1080/14786419.2021.1986818)

To link to this article: <https://doi.org/10.1080/14786419.2021.1986818>



View supplementary material [↗](#)



Published online: 08 Oct 2021.



Submit your article to this journal [↗](#)



Article views: 3



View related articles [↗](#)



View Crossmark data [↗](#)

SHORT COMMUNICATION



LC/MS-MS Analyses and *in vitro* anticancer activity of *Tourneuxia variifolia* extracts

Sara Zerrouki^a , Samia Mezhoud^a , Mustafa Abdullah Yilmaz^b , Ayse Sahin Yaglioglu^c , Derya Bakir^d , Ibrahim Demirtas^e , and Ratiba Mekkiou^a 

^aUnité de recherche: Valorisation des Ressources Naturelles, Molécules Bioactives et Analyses Physicochimiques et Biologiques (VARENBIOMOL), Université des Frères Mentouri Constantine 1, Constantine, Algérie; ^bDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Dicle University, Diyarbakir, Turkey; ^cTechnical Sciences Vocational School, Department of Chemistry and Chemical Process Technology, Amasya University, Amasya, Turkey; ^dThe Council of Forensic Medicine, Diyarbakir Group Chairman ship, Diyarbakir, Turkey; ^eBiochemistry Department, Şehit Bulent Yurtseven Campus, Iğdir University, Faculty of Science and Arts, Iğdir, Turkey

ABSTRACT

Several Saharan plants, despite their abundance of natural compounds, have received little attention. In this study, the chemical composition of polar extracts of *Tourneuxia variifolia* Coss. (Asteraceae), an endemic species to Algerian Sahara, was investigated and their anticancer activity was evaluated *in vitro*. The phytoconstituents of both ethyl acetate (EtOAc) and *n*-butanol (*n*-BuOH) extracts were screened using LC/MS-MS technique. The anticancer activity of the above extracts was measured against human cervical adenocarcinoma (HeLa) cell line. The LC/MS-MS analyses results revealed that twenty-seven phytochemicals in EtOAc extract and twenty-three in *n*-BuOH extract were identified and quantified from which isoquercetin and astragalin were the most present. Moreover; the EtOAc extract was found to have a strong anticancer activity (IC_{50} : $46.797 \pm 0.060 \mu\text{g/mL}$). These findings identified *T. variifolia* as a potential plant exhibiting anticancer properties.


ARTICLE HISTORY

Received 18 July 2021

Accepted 24 September 2021

KEYWORDS

Tourneuxia variifolia; LC/MS-MS; secondary metabolites; HeLa cell line; anticancer activity



1. Introduction

Being a major global public health problem, mortality rates and the incidence of cancer continue to rise. 9.6 million cancer deaths and 18.1 million new cancer cases were estimated in 2018 (Bray et al. 2018). Among men, prostate cancer was second of cancer diagnosed with 15.0%. Globally, cervix cancer is detected to be the third most common cancer among women (Ferlay et al. 2013). Many studies have been conducted on the ability of natural products and their derivatives to inhibit and reverse cancer growth. Surveys indicated that, nearly 80% of cancer patients use natural products in combination with classic anticancer drugs (Dennis et al. 2009). Flavonoids are the best known and most studied (Raj et al. 2001). They have many distinct health benefits (Patil et al. 2009; Crozier et al. 2009), as well as antitumor (Cushman and Nagarathnam 1991; Choi et al. 1999), antiviral (Selway 1986; Wang et al. 1998) and antimitotic (Wang et al. 1998) properties. In this paper, we investigated for the first time, *T. variifolia* Coss. which is an endemic species belonging to the Asteraceae family, as well as the later is the unique in *Tourneuxia* genus. A literature survey showed that there were no studies related to the phytochemical and biological properties of this endemic specie, this lack led us to conduct this study trying to determine the chemical composition of EtOAc and *n*-butanol extracts using LC/MS-MS analyses as well as their anticancer activity.

2. Results and discussion

The EtOAc and *n*-BuOH extracts of *T. variifolia* were analyzed by LC/MS-MS method described and validated by Yilmaz (2020). Twenty-seven and twenty-three compounds were detected and identified with retention time varying between 3.0 to 41.7 min in EtOAc (Figure S1A) and *n*-BuOH (Figure S1B) extracts. An overview of both chromatograms indicates a much greater richness of the EtOAc extract (Figure S1A) in comparison with *n*-BuOH extract (Figure S1B), Both chromatograms show two major peaks at

tr 25.6 and 30.4 min identified as isoquercetin (20.482; 26.004 mg of analyte/g of extract) and astragalin (18.371; 11.902 mg/g of extract) respectively. The other peaks were characterized by the presence of several phenolic acids and flavonoids. The most prominent of which were protocatechuic acid, *p*-coumaric acid, quinic acid, isoquercetin, astragalin, quercetin, rutin, apigenin, luteolin, and kampferol, in addition to other flavonoids and phenolic acids were found in trace amounts.

The anticancer activities of EtOAc and *n*-BuOH extracts for *T. variifolia* and 5-FU were determined against HeLa cells (Figure S2). Although; EtOAc extract (IC₅₀: 46.797 ± 0.060 µg/mL) was detected to have remarkable anticancer activity compared with 5-FU at high concentrations. However; *n*-BuOH extract (IC₅₀: 89.361 ± 0.082 µg/mL) has moderate antiproliferative activity compared with standard at 100 µg/mL concentration. The anticancer activity of both EtOAc and *n*-BuOH extracts of *T. variifolia* in this study was very interesting because of the possible toxic effects of their phytoconstituents. It was shown that quercetin is able to inhibit proliferation of several cancer cell lines at 0–200 µM, 24 h incubation inhibited the cell viability of colon cancer HCT-15 and RKO (De Freitas et al. 2016), and at 0–300 µM, 5 days incubation inhibited the proliferation of the breast cancer and the ovarian cancer cell lines (Granato et al. 2017; Won et al. 2020). In particular, quercetin has also been reported to suppress viability of cervix HeLa cancer cells (Xintaropoulou et al. 2015). Besides; isoquercitrin has been reported to halt the growth of several types of cancer cells such as: selected colon cancer cell lines (Choi et al. 2001), murine carcinoma (Amado et al. 2009), and SK-MEL-2 human skin (Amado et al. 2014) cancer cell lines.

Furthermore; a number of studies have investigated the anticancer activity of astragalin against various cancer cell lines, including: hepatocellular carcinoma and lung cancer (Chen et al. 2017; Li et al. 2017) and human leukemia cells (Burmistrova et al. 2011). On the other hand, Yin et al. 2009 reported that at lower concentrations of protocatechuic acid could provide apoptotic effects in human breast, lung, liver, prostate and cervix cancer cells.

3. Conclusion

For the first time, *Tourneuxia variifolia* aerial parts extracts were subjected to LC/MS-MS analyses to identify and quantify phenolic and flavonoid components, as well as to assess their biological activities. The investigation of both EtOAc and *n*-BuOH extracts of *T. variifolia* yielded the identification of twenty-eight chemicals with high quantities of glycolysated flavonoids. Finally; this study shows that EtOAc and *n*-BuOH extracts have potent anticancer properties, owing to the presence of phenolic compounds in the extracts. Based on these findings, *T. variifolia* could be identified as a potential plant exhibiting anticancer properties

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the Algerian Ministry of Higher Education and Scientific Research (MESRS) and the Algerian PRFU (B00L01UN250120180002) program.

Abbreviations

EtOAc Ethyl acetate
n-BuOH *n*-butanol

ORCID

Sara Zerrouki  <http://orcid.org/0000-0003-1266-5280>
 Samia Mezhoud  <http://orcid.org/0000-0002-1698-5188>
 Mustafa Abdullah Yilmaz  <http://orcid.org/0000-0002-4090-7227>
 Ayse Sahin Yaglioglu  <http://orcid.org/0000-0002-7668-6286>
 Derya Bakir  <http://orcid.org/0000-0002-1040-4370>
 Ibrahim Demirtas  <http://orcid.org/0000-0001-8946-647X>
 Ratiba Mekkiou  <http://orcid.org/0000-0002-5283-3501>

References

- Amado NG, Cerqueira DM, Menezes FS, Mendes da Silva JF, Neto VM, Abreu JG. 2009. Isoquercitrin isolated from *Hyptis fasciculata* reduces glioblastoma cell proliferation and changes beta-catenin cellular localization. *Anticancer Drugs*. 20(7):543–552.
- Amado NG, Predes D, Fonseca BF, Cerqueira DM, Reis AH, Dudenhoefter AC, Borges HL, Mendes FA, Mendes JG. 2014. Isoquercitrin suppresses colon cancer cell growth *in vitro* by targeting the Wnt/ β -catenin signaling pathway. *J Biol Chem*. 289(51):35456–35457.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 68(6):394–424..
- Burmistrova O, Quintana J, Diaz JG, Estevez F. 2011. Astragalin heptaacetate-induced cell death in human leukemia cells is dependent on caspases and activates the MAPK pathway. *Cancer Lett*. 309(1):71–77..
- Chen M, Cai F, Zha D, Zha D, Wang X, Zhang W, He Y, Huang Q, Zhuang H, Hua Z. 2017. Astragalin-induced cell death is caspase-dependent and enhances the susceptibility of lung cancer cells to tumor necrosis factor by inhibiting the NF- κ B pathway. *Oncotarget*. 8(16): 26941–26958. 10.18632/oncotarget.15264.
- Crozier A, Jaganath IB, Clifford MN. 2009. Dietary phenolics: chemistry, bioavailability and effects on health. *Nat Prod Rep*. 26(8):1001–1043.
- Cushman M, Nagarathnam D. 1991. Cytotoxicities of some flavonoid analogues. *J Nat Prod*. 54(6):1656–1660..
- Choi SU, Ryu SY, Yoon SK, Jung NP, Park SH, Kim KH, Choi EJ, Co L. 1999. Effects of flavonoids on the growth and cell cycle of cancer cells. *Anticancer Res*. 19(6B):5229–5233.
- Choi JA, Kim JY, Lee JY, Kang CM, Kwon HJ, Yoo YD, Kim TW, Lee YS, Lee SJ. 2001. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. *Int J Oncol*. 19 (4): 837–844..
- Dennis T, Fanous M, Mousa S. 2009. Natural products for chemopreventive and adjunctive therapy in oncologic disease. *Nutr Cancer*. 61(5):587–597..
- De Freitas MM, Fontes P, De Souza PM, Fagg CW, Guerra ENS, Nóbrega YKDM, Silveira D, Fonseca-Bazzo Y, Simeoni LA, Homem-De-Mello M, et al. 2016. Extracts of *Morus nigra* L. leaves standardized in chlorogenic acid, rutin and isoquercitrin: tyrosinase inhibition and cytotoxicity. *PLoS One*. 11(9):e0163130..

- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. [2013](#). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer*. 49(6):1374–1403..
- Granato M, Rizzello C, Gilardini Montani MS, Cuomo L, Vitillo M, Santarelli R, Gonnella R, D'Orazi G, Faggioni A, Cirone M. [2017](#). Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. *J Nutr Biochem*. 41:124–136..
- Li W, Hao J, Zhang L, Cheng Z, Deng X, Shu G. [2017](#). Astragalin reduces hexokinase 2 through increasing miR 125b to inhibit the proliferation of hepatocellular carcinoma cells *in vitro* and *in vivo*. *J Agric Food Chem*. 65(29):5961–5972..
- Patil BS, Jayaprakasha GK, Chidambara Murthy KN, Vikram A. [2009](#). Bioactive compounds: historical perspectives, opportunities, and challenges. *J Agric Food Chem*. 57(18):8142–8160..
- Raj NK, Sripal RM, Chaluvadi MR, Krishna DR. [2001](#). Bioflavonoids: classification, pharmacological, biochemical effects and therapeutic potential. *Indian J Pharmacol*. 33:2–16.
- Selway JW. [1986](#). Antiviral activity of flavones and flavans. *Prog Clin Biol Res*. 213:521–536.
- Wang HK, Xia Y, Yang ZY, Natschke SL, Lee KH. [1998](#). Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. *Adv Exp Med Biol*. 439:191–225.
- Won YS, Kim JH, Lizardo RCM, Min HJ, Cho HD, Hong SM, Seo KI. [2020](#). The flavonol isoquercitrin promotes mitochondrial-dependent apoptosis in SK-Mel-2 melanoma cell via the PI3K/AKT/mTOR pathway. *Nutrients*. 12(12):3683..
- Xintaropoulou C, Ward C, Wise A, Marston H, Turnbull A, Langdon SP. [2015](#). A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models. *Oncotarget*. 6 (28):25677–25695. 10.18632/oncotarget.4499.
- Yin MC, Lin CC, Wu HC, Tsao SM, Hsu CK. [2009](#). Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix and prostate cancer cells: potential mechanisms of action. *J Agric Food Chem*. 57(14):6468–6473.